Tinlarebant (LBS-008)

Name: Tinlarebant (LBS-008) in Stargardt disease type 1: Economic impact of diagnostic testing
Published: 2026-09-14T15:39:06-04:00

Stargardt disease type 1

Manufacturer: Belite Bio
Regulatory submission: NDA submitted June 2026
Launch: Anticipated in March 2027
Last updated: September 19, 2026

Section

Product information and disease description Place of product in therapy Disease description Burden of Stargardt disease type 1

Economic impact of diagnostic testing

2 evidence topics · 1 source

South Africa: time-limited 2025 genetic-testing offer

“A total fee of R6000 will cover your DNA testing” (opens the source at this quote in a new tab)
“but only until August 2025.” (opens the source at this quote in a new tab)

South Africa: additional genetic-counseling consultation cost

“(± R1600, often covered by medical aids).” (opens the source at this quote in a new tab)